Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: CSJ117
Drug: Placebo

First Posted Date: 2021-05-11

Last Posted Date: 2022-11-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 38

Registration Number: NCT04882124

Locations: 🇯🇵
Novartis Investigative Site, Naka-gun, Ibaraki, Japan

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Phase 4

Terminated

Conditions: Relapsing Multiple Sclerosis (RMS)

Interventions: Drug: Ofatumumab
Biological: mRNA COVID-19 vaccine
Drug: interferon or glatiramer acetate

First Posted Date: 2021-05-07

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT04878211

Locations: 🇺🇸
Dragonfly Research LLC, Wellesley, Massachusetts, United States
🇺🇸
Minnesota Center Multiple Sclerosis, Plymouth, Minnesota, United States
🇺🇸
The MS Center for Innovation in Care, Saint Louis, Missouri, United States

and more 4 locations

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Phase 2

Completed

Conditions: Myelodysplastic Syndrome (MDS)

Interventions: Drug: MBG453
Drug: Azacitidine
Drug: Decitabine
Drug: INQOVI (oral decitabine)

First Posted Date: 2021-05-07

Last Posted Date: 2024-10-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 39

Registration Number: NCT04878432

Locations: 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸
University Hospitals Of Cleveland, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 12 locations

Asciminib Roll-over Study

Phase 4

Recruiting

Conditions: Chronic Myelogenous Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions: Drug: Bosutinib
Drug: Imatinib
Drug: Asciminib single agent
Drug: Nilotinib
Drug: Dasatinib

First Posted Date: 2021-05-07

Last Posted Date: 2024-12-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 347

Registration Number: NCT04877522

Locations: 🇺🇸
Michigan Med University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States

and more 2 locations

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

Phase 3

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Inclisiran

First Posted Date: 2021-05-05

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 400

Registration Number: NCT04873934

Locations: 🇺🇸
Reliant Medical Research, Miami, Florida, United States
🇺🇸
Meridian Clinical Research, Lincoln, Nebraska, United States
🇺🇸
Longwood Research, Huntsville, Alabama, United States

and more 92 locations

Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab

Phase 4

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Ofatumumab

First Posted Date: 2021-05-03

Last Posted Date: 2024-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT04869358

Locations: 🇩🇪
Novartis Investigative Site, Unterhaching, Germany

Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)

Phase 2

Completed

Conditions: Familial Cold Autoinflammatory Syndrome

Interventions: Drug: DFV890

First Posted Date: 2021-05-03

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 4

Registration Number: NCT04868968

Locations: 🇩🇪
Novartis Investigative Site, Tuebingen, Germany

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

Phase 2

Active, not recruiting

Conditions: Osteoarthritis

Interventions: Drug: LNA043 Dosing Regimen A
Drug: LNA043 Dosing Regimen B
Drug: LNA043 Dosing Regimen C
Drug: LNA043 Dosing Regimen D
Drug: Placebo

First Posted Date: 2021-04-28

Last Posted Date: 2024-12-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 585

Registration Number: NCT04864392

Locations: 🇺🇸
Elite Clinical Studies, Phoenix, Arizona, United States
🇺🇸
Tucson Orthopedic Institute PC, Tucson, Arizona, United States
🇺🇸
Clinical Trials Research, Lincoln, California, United States

and more 21 locations

Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant

Phase 2

Terminated

Conditions: Advanced Breast Cancer

Interventions: Drug: Alpelisib
Drug: Fulvestrant
Drug: Goserelin

First Posted Date: 2021-04-27

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2

Registration Number: NCT04862143

Locations: 🇸🇪
Novartis Investigative Site, Orebro, Sweden

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

Phase 1

Recruiting

Conditions: Mesothelioma

Interventions: Drug: IAG933

First Posted Date: 2021-04-23

Last Posted Date: 2024-12-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 156

Registration Number: NCT04857372

Locations: 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸
Uni of Chi Medi Ctr Hema and Onco, Chicago, Illinois, United States
🇺🇸
Sidney Kimmel CCC At JH, Baltimore, Maryland, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy